Leo Wealth LLC Purchases 1,833 Shares of Hologic, Inc. (NASDAQ:HOLX)

Leo Wealth LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 40.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,335 shares of the medical equipment provider’s stock after purchasing an additional 1,833 shares during the period. Leo Wealth LLC’s holdings in Hologic were worth $494,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Orion Portfolio Solutions LLC increased its position in Hologic by 2.8% in the 1st quarter. Orion Portfolio Solutions LLC now owns 65,407 shares of the medical equipment provider’s stock valued at $5,099,000 after acquiring an additional 1,785 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Hologic by 15.3% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 278,181 shares of the medical equipment provider’s stock valued at $21,687,000 after purchasing an additional 36,898 shares during the period. State Board of Administration of Florida Retirement System raised its position in Hologic by 2.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 291,729 shares of the medical equipment provider’s stock worth $23,543,000 after purchasing an additional 6,198 shares during the last quarter. TD Asset Management Inc lifted its holdings in Hologic by 2.0% during the 1st quarter. TD Asset Management Inc now owns 1,934,841 shares of the medical equipment provider’s stock worth $150,840,000 after buying an additional 37,136 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Hologic by 18.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock valued at $170,297,000 after buying an additional 338,212 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.6 %

HOLX stock traded up $0.45 during trading on Friday, reaching $78.11. 1,660,472 shares of the stock were exchanged, compared to its average volume of 1,628,747. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $82.45. The firm’s 50 day moving average is $74.26 and its 200 day moving average is $74.78. The firm has a market cap of $18.23 billion, a P/E ratio of 39.85, a price-to-earnings-growth ratio of 2.63 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. Hologic’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.06 earnings per share. As a group, research analysts forecast that Hologic, Inc. will post 4.08 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on HOLX shares. JPMorgan Chase & Co. lifted their price objective on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Stephens began coverage on shares of Hologic in a research report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 price target on the stock. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Friday, May 3rd. Finally, StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus price target of $85.55.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.